Related Experiment Videos
Plasma adiponectin and gastric cancer
Makoto Ishikawa1, Joji Kitayama, Shinsuke Kazama
1Department of Surgery, Division of Surgical Oncology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. makoto-ishi@umin.ac.jp
Summary
Low adiponectin levels are linked to increased gastric cancer risk. This study found lower adiponectin in gastric cancer patients, especially those with upper, undifferentiated tumors, suggesting a role in cancer progression.
Area of Science:
- Oncology
- Endocrinology
- Biochemistry
Background:
- Obesity is a known risk factor for various cancers, including gastric cancer.
- Adiponectin, a hormone from adipose tissue, influences cell proliferation and insulin sensitivity.
- Circulating adiponectin levels are inversely correlated with body mass index.
Purpose of the Study:
- To investigate the association between plasma adiponectin levels and gastric cancer risk.
- To explore the relationship between adiponectin levels and clinicopathologic characteristics of gastric cancer.
Main Methods:
- Fasting plasma adiponectin levels were measured using ELISA in 75 gastric cancer patients and 52 healthy controls.
- Statistical analyses were performed to assess the association between adiponectin levels, gastric cancer risk, and clinicopathologic features.
Main Results:
- Gastric cancer patients exhibited significantly lower plasma adiponectin levels compared to healthy controls (9.1 vs. 13.3 ng/mL, P < 0.01).
- Lower adiponectin levels were associated with an increased risk of gastric cancer (OR, 0.92; adjusted OR, 0.89).
- Adiponectin levels were notably lower in upper gastric cancers and tended to decrease with advanced tumor stage. A negative correlation was observed between adiponectin and tumor progression markers in undifferentiated cancers.
Conclusions:
- Low plasma adiponectin levels are associated with elevated gastric cancer risk.
- Adiponectin may play a role in gastric cancer progression, particularly in undifferentiated upper gastric tumors.